Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other financing activities: 2021-2025

Historic Other financing activities for InMed Pharmaceuticals (INM) over the last 1 years, with Sep 2025 value amounting to $137,178.

  • InMed Pharmaceuticals' Other financing activities fell 28.49% to $137,178 in Q3 2025 from the same period last year, while for Sep 2025 it was $418,064, marking a year-over-year decrease of 56.70%. This contributed to the annual value of $883,978 for FY2025, which is 57.25% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Other financing activities stood at $137,178 for Q3 2025, which was down 28.49% from $191,824 recorded in Q3 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Other financing activities peaked at $1.1 million during Q3 2021, and registered a low of $25,191 during Q3 2023.
  • For the 3-year period, InMed Pharmaceuticals' Other financing activities averaged around $104,516, with its median value being $100,524 (2023).
  • Per our database at Business Quant, InMed Pharmaceuticals' Other financing activities crashed by 95.59% in 2023 and then soared by 661.48% in 2024.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Other financing activities stood at $179,118 in 2021, then spiked by 282.23% to $684,650 in 2022, then tumbled by 95.59% to $25,191 in 2023, then spiked by 661.48% to $191,824 in 2024, then declined by 28.49% to $137,178 in 2025.
  • Its Other financing activities was $137,178 in Q3 2025, compared to $191,824 in Q3 2024 and $25,191 in Q3 2023.